You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
72 search results for: type 2 inflammation
expert video
Itch in AD, PN, and CSU: Contributions of Type2Inflammation
Dermatology
In this video from the ADVENT symposium from Fall Clinical 2023, join Dr. Raj Chovatiya as he explores the contribution of type2inflammation to itch in AD, PN, and CSU.
A Common Link: The Role of Type2Inflammation in the Clinical Presentation of AD, PN, and CSU
Dermatology
In this video from the ADVENT symposium at Fall Clinical 2023, join Dr. James Del Rosso as he explores the role of type2inflammation in the clinical presentation of AD, PN, and CSU.
In COPD, blood eosinophil testing is one of the five core assessments for initial patient evaluation, according to the GOLD Report. This infographic illustrates the role that blood eosinophils, as a biomarker for type2inflammation, play in predicting exacerbation risk and other COPD outcomes, and provides information from the GOLD Report on when to test for blood eosinophils and how eosinophils may guide patient management.
A Tale of Two Itches: Bridging the Gap With Type2Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria
Dermatology
Dr. Elmariah, Professor Metz, and Dr. Kim discuss the unique clinical presentations of PN and CSU and explore the shared and distinct pathophysiological underpinnings of itch and inflammation in both diseases, with a focus on the roles of type2 cytokines at the neuroimmune axis In PN and CSU
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.